Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.
Vaccine manufacturer Indian Immunologicals and Griffith University in Australia have partnered to develop a potential vaccine candidate against Covid-19.
The partners intend to create a live attenuated vaccine using codon de-optimisation technology, which would offer longer protection with a single dose.
In a statement, Indian Immunologicals said: “The technology looks promising for developing a vaccine for prophylactic, active, single-dose immunisation against coronavirus in humans, with an enhanced safety profile.
“The vaccine is expected to provide long-lasting protection with a single dose administration with an anticipated safety profile similar to other licensed vaccines for active immunisation.”
After research completion, the vaccine strain will be transferred to the company, which will be responsible for further development, including clinical trials.
The company plans to use its Vero cell platform technology for mass production of the vaccine.
Griffith University Menzies Health Institute Queensland researcher Suresh Mahalingam said: “As this vaccine will be a live attenuated vaccine it is expected to be highly effective by providing very strong cellular and antibody immune responses against the virus.
“The other benefit of a live-attenuated vaccine is a proven track record for economical large-scale manufacturing and well-known regulatory approval pathway.”
Previously, Indian Immunologicals partnered with the Australian university for the research and development of Zika virus vaccine, now undergoing pre-clinical toxicology testing.
In February, Serum Institute of India forged an alliance with US-based Codagenix to develop a Covid-19 vaccine candidate. The vaccine candidate entered animal testing phase and data from mice and primates is expected by the end of August.
Serum Institute of India estimates that the vaccine candidate will enter clinical trials in the coming six months.